A Phase 2 interventional study of GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A and Placebo in Neoplasms, Breast, sponsored by GlaxoSmithKline. Terminated at 36 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-25.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 349 studies testing Aromatase inhibitors in Breast Neoplasms — 53 open to participants now, 81 under way, 22 of them phase 3. A drug class: Aromatase inhibitors · Breast Neoplasms.
Among the 349 studies testing Aromatase inhibitors in Breast Neoplasms, this one is the 212th largest by enrollment of the 341 interventional ones that give a count, is one of 10 that started in 2011, is one of 166 in phase 2, and was the 157th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.
Browse Breast Neoplasms studies →53 of the 349 studies testing Aromatase inhibitors in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Women only
European Institute of Oncology · Sites in Italy
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Women only
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 50+ · Women only
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18+ · Women only
By country, each count listing its studies:
A class of medicines: which ones, and the studies of each, are on its page →
Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
349 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 27 · Phase 2 181 · Phase 3 107 · Phase 4 28
First in 1990; this study’s year is marked. 10 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 66 is close to the median of 72 across 10,903 interventional studies indexed under Breast Neoplasms.
Median enrollment 112 across the 341 interventional studies. Of the 225 that completed or were terminated, 96 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
79 of 349 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
59 studies in Breast Neoplasms by GlaxoSmithKline: 1 open now, 3 under way, 1 of them phase 3. Of 53 finished, 26 (49%) have results posted.
Among the 59 studies in Breast Neoplasms by GlaxoSmithKline, this one is the 23rd largest by enrollment of the 51 interventional ones that give a count, is one of 3 that started in 2011, is one of 26 in phase 2, and was the 45th registered.
GlaxoSmithKline’s Breast Neoplasms studies by the year they started, since 2002.
15 of the studies testing Aromatase inhibitors in Breast Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05780567Phase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer | 2026-12 |
| NCT01953588Phase 3Alliance for Clinical Trials in OncologyFulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery | 2027-04-01 |
| NCT04486911Shengjing HospitalPyrotinib Maleate, CDK4/6 Inhibitor and Letrozole in Combination for Stage II-III TPBC: a Phase II Trial | 2026-12-01 |
| NCT05286437National Cancer Centre, SingaporePhase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole | 2026-12-31 |
| NCT07492394Hebei Medical University Fourth HospitalDalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 349 studies testing Aromatase inhibitors in Breast Neoplasms, from their registry updates:
Among GlaxoSmithKline’s 59 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, immunogenicity and clinical activity of a new WT1 anti-cancer immunotherapy in patients with WT1-positive Stage II or III breast cancer. The treatment will be given before surgery in combination with standard therapy.
The study will be conducted in two consecutive segments (Phase I and Phase II), each with specific objectives. Active follow-up will be for three years.
Patients in this study will be allocated to cohorts as below. Cohort A will include postmenopausal patients with hormone receptor-positive breast cancer who receive aromatase inhibitor (AI) as neoadjuvant therapy concurrently with administration of 6 or 8 doses of WT1 anti-cancer immunotherapy (WT1 ASCI)/placebo starting on Day 0. AI treatment will be administered daily for duration of either 18 (if 6 doses of WT1 ASCI/placebo) or 24 weeks (if 8 doses of WT1 ASCI/placebo).
Cohort B will include breast cancer patients who will receive neoadjuvant chemotherapy concurrently with administration of WT1 ASCI/placebo starting on Day 0. Neoadjuvant chemotherapy in Cohort B will consist either 1) if 6 doses of WT1 ASCI/placebo: 6 cycle-treatment chemotherapy regimens consist of 6, three-weekly cycles of anthracycline/taxane-based therapy, or 2) if 8 doses of WT1 ASCI/placebo: 8 cycle-treatment regimens consisting of 4 three-weekly cycles of anthracycline-based therapy followed by 4 three-weekly or 12-weekly taxane administrations without trastuzumab.
Cohort C will include patients with Human Epidermal Growth Factor Receptor 2 (HER2)-overexpressing breast cancer who will receive neoadjuvant trastuzumab (Herceptin) therapy combined with chemotherapy concurrently with administration of WT1 ASCI/placebo starting on Day 0. Neoadjuvant chemotherapy in Cohort C will consist either 1) if 6 doses of WT1 ASCI/placebo: 6 cycle-treatment chemotherapy regimens consist of 6, three-weekly cycles of anthracycline/taxane-based therapy, or 2) if 8 doses of WT1 ASCI/placebo: 8 cycle-treatment regimens consisting of 4 three-weekly cycles of anthracycline-based therapy followed by 4 three-weekly or 12-weekly taxane administrations with trastuzumab.
Cohorts D and E will include patients with hormone receptor-positive and HER2 non-overexpressing breast cancer who will receive neoadjuvant chemotherapy. For patients in these Cohorts D and E, WT1 ASCI/placebo (placebo applicable only for Cohort E patients) will be administered on Day 14 of each three-weekly cycle of chemotherapy. Neoadjuvant chemotherapy in Cohorts D and E will consist either 1) if 6 doses of WT1 ASCI/placebo: 6 cycle-treatment chemotherapy regimens consist of 6, three-weekly cycles of anthracycline/taxane-based therapy, or 2) if 8 doses of WT1 ASCI/placebo: 8 cycle-treatment regimens consisting of 4 three-weekly cycles of anthracycline-based therapy followed by 4 three-weekly taxane administrations without trastuzumab. Enrolment in Cohort E will be conditional on the absence of a safety signal and on the adequate induction of an immune response by the WT1 ASCI in Cohort D (defined as >= 40% response rate based on post-Dose 4 anti-WT1 antibody responses in at least six patients). If this criterion is met, 60 patients (40 receiving WT1 ASCI and 20 placebo) with identical eligibility criteria will be enrolled into Cohort E. In case no adequate safety and/or immunogenicity will be obtained in Cohort D, recruitment in Cohort E will not be initiated.
The protocol has been updated following Protocol Amendment 4, April 2013, leading to the update of the study design.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Isolated supraclavicular lymph node involvement is allowed.
The patient has one of the following histologically confirmed breast cancer subtypes:
The patient shows normal organ function according to the following parameters(as measured within six weeks prior to treatment allocation)::
A female patient of may be enrolled in the study, if the patient:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group included postmenopausal patients with hormone receptor-positive breast cancer who received aromatase inhibitor (AI) as neoadjuvant therapy, concurrently with administration of GSK2302024A according to the treatment schedule.
Biological: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A · Drug: Aromatase inhibitor
This group included postmenopausal patients with hormone receptor-positive breast cancer who received aromatase inhibitor (AI) as neoadjuvant therapy, concurrently with administration of placebo, according to the treatment schedule.
Drug: Placebo · Drug: Aromatase inhibitor · Drug: 5-Fluorouracil · Drug: Cyclophosphamide · Drug: Docetaxel · Drug: Doxorubicin · Drug: Epirubicin · Drug: Paclitaxel
This group included breast cancer patients who received GSK2302024A, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
Biological: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A · Drug: 5-Fluorouracil · Drug: Cyclophosphamide · Drug: Docetaxel · Drug: Doxorubicin · Drug: Epirubicin · Drug: Paclitaxel
This group included breast cancer patients who received placebo, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
Drug: Placebo · Drug: 5-Fluorouracil · Drug: Cyclophosphamide · Drug: Docetaxel · Drug: Doxorubicin · Drug: Epirubicin · Drug: Paclitaxel
This group included patients with Human Epidermal Growth Factor Receptor 2 (HER2)-overexpressing breast cancer who received neoadjuvant trastuzumab (Herceptin) therapy, concurrently with administration of GSK2302024A, 5-Fluorouracil, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
Biological: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A · Drug: 5-Fluorouracil · Drug: Carboplatin AUC · Drug: Cyclophosphamide · Drug: Docetaxel · Drug: Doxorubicin · Drug: Epirubicin · Drug: Paclitaxel · Drug: Trastuzumab
This group included patients with Human Epidermal Growth Factor Receptor 2 (HER2)-overexpressing breast cancer who received neoadjuvant trastuzumab (Herceptin) therapy, concurrently with administration of placebo, 5-Fluorouracil, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
Drug: Placebo · Drug: 5-Fluorouracil · Drug: Carboplatin AUC · Drug: Cyclophosphamide · Drug: Docetaxel · Drug: Doxorubicin · Drug: Epirubicin · Drug: Paclitaxel · Drug: Trastuzumab
This group included patients with hormone receptor-positive and HER2 non-overexpressing breast cancer, who received GSK2302024A, 5-Fluorouracil, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin and Paclitaxel according to the treatment schedule.
Biological: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A · Drug: 5-Fluorouracil · Drug: Cyclophosphamide · Drug: Docetaxel · Drug: Doxorubicin · Drug: Epirubicin · Drug: Paclitaxel
6 or 8 injections at 3 weeks apart, injected intramuscularly in the deltoid or lateral region of the thigh.
Also known as: WT1 ASCI
6 or 8 doses at 3 weeks apart of sucrose/mannitol-based formulation reconstituted with an oil-in-water emulsion, injected intramuscularly in the deltoid or lateral region of the thigh.
This treatment consisted of any aromatase inhibitor (e.g. letrozole or exemestane), administered intravenously in Cohort A Groups daily for either 18 (if 6 doses of WT1 ASCI/placebo) or 24 weeks (if 8 doses of WT1 ASCI/placebo).
Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses at 3 weeks apart, and for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
Administered intravenously in Cohort C Groups in 6 doses at 3 weeks apart, on the same day as WT1 ASCI/placebo administration (Day 1 of each cycle).
Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses in Cohort C Groups and 6 doses 3 weeks apart in Cohorts A Placebo, B and D Groups, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 or 6 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 6 doses 3 weeks apart (Cohort C patients with this schedule did not receive this treatment), while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: only in the 8 WT1 ASCI-dose schedule patients received 4 at 3 weeks apart or 12 weekly doses. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
Administered intravenously in Cohort C Groups: for the 6 WT1 ASCI-dose schedule 3 or 6 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
This study also gives Exemestane. No intervention listed here names it: that was found by reading the record.
Number of Subjects With Severe Toxicities
Severe toxicity was defined as follows: - A Grade 3 or higher toxicity that is related or possibly related to the combined administration of standard treatment and GSK2302024A/placebo - A decrease in Left Ventricular Ejection Fraction (LVEF) from baseline with ≥ 10 points and at \< 50% that is related or possibly related to the combined administration of treatment and that is confirmed by a second LVEF assessment within approximately 3 weeks. - A Grade 2 or higher cardiac ischemia/infarction that is related or possibly related to the combined administration of standard treatment and GSK2302024A /placebo. - A Grade 2 or higher allergic reaction occurring within 24 hours following the administration. - A Grade 3 or higher blood/bone marrow toxicity that was considered as related or possibly related to the combined Administration. - A decrease in renal function at the time of administration that was considered as related or possibly related.
Time frame: From Week 0 to Week 26/32 (period starting from GSK2302024A/placebo treatment allocation and ending with the concluding Visit i.e.: Week 26 for patients receiving 6 injections and Week 32 for patients receiving 8 injections)
Number of Patients With an Anti-Wilm's Tumor Gene (Anti-WT1) Humoral Response
For initially seronegative patients: post-administration antibody concentration ≥ 9 EU/mL For initially seropositive patients: post-administration antibody concentration ≥ 2 fold the pre-administration antibody concentration.
Time frame: At post-GSK2302024A/placebo Dose 4 (Week 13)
Number of Patients With Adverse Events (AEs)
An AE is any untoward medical occurrence in a clinical investigation patient, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e., lack of efficacy), abuse or misuse.
Time frame: During the treatment period and up to 30 days post last administration
Number of Subjects With Serious Adverse Events SAE(s)
A serious adverse event (SAE) is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of hospitalization, causes disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study patient. In this study, an event which was part of the natural course of the disease under study (i.e., disease progression/recurrence) was captured in the study/as an efficacy measure. Therefore it was not reported as an SAE. Progression/recurrence of the tumor was recorded in the clinical assessments in the electronic case report form (eCRF). Death due to progressive disease was recorded on a specific form in the eCRF but not as an SAE.
Time frame: From Week 0 to Week 26/32 (period starting from GSK2302024A/placebo treatment allocation and ending with the concluding Visit i.e.: Week 26 for patients receiving 6 injections and Week 32 for patients receiving 8 injections)
Number of Subjects With Alanine Aminotransferase Increased Abnormality, by Common Terminology Criteria for Adverse Events (CTCAE) Maximum Grade
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
Time frame: During the treatment period and up to 30 days post last administration
Number of Subjects With Alkaline Phosphatase Increased Abnormality, by CTCAE Maximum Grade
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
Time frame: During the treatment period and up to 30 days post last administration
Number of Subjects With Anemia, by CTCAE Maximum Grade
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
Time frame: During the treatment period and up to 30 days post last administration
Number of Subjects With Aspartate Aminotransferase Increased Abnormality, by CTCAE Maximum Grade
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
Time frame: During the treatment period and up to 30 days post last administration
Number of Subjects With Blood Bilirubin Increased Abnormality, by CTCAE Maximum Grade
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
Time frame: During the treatment period and up to 30 days post last administration
Number of Subjects With Creatine Increased Abnormality, by CTCAE Maximum Grade
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
Time frame: During the treatment period and up to 30 days post last administration
Number of Subjects With Hemoglobin Increased Abnormality, by CTCAE Maximum Grade
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
Time frame: During the treatment period and up to 30 days post last administration
Number of Subjects With Hypercalcemia Abnormality, by CTCAE Maximum Grade
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
Time frame: During the treatment period and up to 30 days post last administration
Number of Subjects With Hyperkalemia Abnormality, by CTCAE Maximum Grade
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
Time frame: During the treatment period and up to 30 days post last administration
Number of Subjects With Hypernatremia Abnormality, by CTCAE Maximum Grade
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
Time frame: During the treatment period and up to 30 days post last administration
Number of Subjects With Hypoalbuminemia Abnormality, by CTCAE Maximum Grade
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
Time frame: During the treatment period and up to 30 days post last administration
Number of Subjects With Hypocalcemia Abnormality, by CTCAE Maximum Grade
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
Time frame: During the treatment period and up to 30 days post last administration
Number of Subjects With Hypokalemia Abnormality, by CTCAE Maximum Grade
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
Time frame: During the treatment period and up to 30 days post last administration
Number of Subjects With Hyponatremia Abnormality, by CTCAE Maximum Grade
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
Time frame: During the treatment period and post 30 days post last administration
Number of Subjects With Lymphocyte Count Decreased Abnormality, by CTCAE Maximum Grade
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
Time frame: During the treatment period and up to 30 days post last administration
Number of Subjects With Lymphocyte Count Increased Abnormality, by CTCAE Maximum Grade
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
Time frame: During the treatment period and up to 30 days post last administration
Number of Subjects With Neutrophil Count Decreased Abnormality, by CTCAE Maximum Grade
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
Time frame: During the treatment period and up to 30 days post last administration
Number of Subjects With Platelet Count Decreased Abnormality, by CTCAE Maximum Grade
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
Time frame: During the treatment period and up to 30 days post last administration
Number of Subjects With White Blood Cell Decreased Abnormality, by CTCAE Maximum Grade
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
Time frame: During the treatment period and up to 30 days post last administration
Number of Patients With Adverse Events (AEs), by CTCAE Maximum Grade Reported
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
Time frame: During the treatment period and up to 30 days post last administration
Number of Subjects With Adverse Events (AEs) Assessed by the Investigators as Causally Related to GSK2302024A Treatment, by CTCAE Maximum Grade Reported
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
Time frame: During the treatment period and up to 30 days post last administration
Number of Subjects With Serious Adverse Events (SAEs), by CTCAE Maximum Grade Reported
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
Time frame: During the treatment period and up to 30 days post last administration
Number of Subjects With Serious Adverse Events (SAEs), Assessed by the Investigators as Causally Related to GSK2302024A Treatment, by CTCAE Maximum Grade Reported
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
Time frame: During the treatment period and up to 30 days post last administration
Number of Subjects With Breast Cancer Pathological Response
The pathological response in lymph nodes was evaluated by presence or absence of tumor cells by histopathological examination. Partial responses mark the disappearance of tumor cells, with only small clusters or dispersed cells remaining (more than 90% loss) while complete response indicate no identifiable malignant cells. However, ductal carcinoma in situ may be present.
Time frame: During the treatment period, up to Week 26/32
Out of the 66 enrolled patients, 6 patients did not receive study product doses and were hence excluded prior to study start.
| Milestone | Cohort A-GSK2302024A Group | Cohort A-Placebo Group | Cohort B-GSK2302024A Group | Cohort B-Placebo Group | Cohort C-GSK2302024A Group | Cohort C-Placebo Group | Cohort D-GSK2302024A-D14 Group |
|---|---|---|---|---|---|---|---|
| Started | 15 | 7 | 9 | 6 | 11 | 4 | 8 |
| Completed | 11 | 6 | 6 | 6 | 11 | 4 | 3 |
| Not completed | 4 | 1 | 3 | 0 | 0 | 0 | 5 |
| Withdrew: Progressive disease | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Sponsor study termination | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event, serious fatal | 2 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event, non-fatal | 1 | 0 | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Other | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Consent withdrawn by subject | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
Severe toxicity was defined as follows: - A Grade 3 or higher toxicity that is related or possibly related to the combined administration of standard treatment and GSK2302024A/placebo - A decrease in Left Ventricular Ejection Fraction (LVEF) from baseline with ≥ 10 points and at \< 50% that is related or possibly related to the combined administration of treatment and that is confirmed by a second LVEF assessment within approximately 3 weeks. - A Grade 2 or higher cardiac ischemia/infarction that is related or possibly related to the combined administration of standard treatment and GSK2302024A /placebo. - A Grade 2 or higher allergic reaction occurring within 24 hours following the administration. - A Grade 3 or higher blood/bone marrow toxicity that was considered as related or possibly related to the combined Administration. - A decrease in renal function at the time of administration that was considered as related or possibly related.
| Subjects | Cohort A-GSK2302024A Group | Cohort A-Placebo Group | Cohort B-GSK2302024A Group | Cohort B-Placebo Group | Cohort C-GSK2302024A Group | Cohort C-Placebo Group | Cohort D-GSK2302024A-D14 Group |
|---|---|---|---|---|---|---|---|
| Number of Subjects With Severe Toxicities | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
For initially seronegative patients: post-administration antibody concentration ≥ 9 EU/mL For initially seropositive patients: post-administration antibody concentration ≥ 2 fold the pre-administration antibody concentration.
| Subjects | Cohort A-GSK2302024A Group | Cohort A-Placebo Group | Cohort B-GSK2302024A Group | Cohort B-Placebo Group | Cohort C-GSK2302024A Group | Cohort C-Placebo Group | Cohort D-GSK2302024A-D14 Group |
|---|---|---|---|---|---|---|---|
| Number of Patients With an Anti-Wilm's Tumor Gene (Anti-WT1) Humoral Response | 10 | 0 | 0 | 0 | 6 | 0 | 2 |
An AE is any untoward medical occurrence in a clinical investigation patient, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e., lack of efficacy), abuse or misuse.
| Subjects | Cohort A-GSK2302024A Group | Cohort A-Placebo Group | Cohort B-GSK2302024A Group | Cohort B-Placebo Group | Cohort C-GSK2302024A Group | Cohort C-Placebo Group | Cohort D-GSK2302024A-D14 Group |
|---|---|---|---|---|---|---|---|
| Number of Patients With Adverse Events (AEs) | 15 | 5 | 9 | 6 | 11 | 4 | 7 |
A serious adverse event (SAE) is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of hospitalization, causes disability/incapacity or is a congenital anomaly/birth defect in the offspring of a study patient. In this study, an event which was part of the natural course of the disease under study (i.e., disease progression/recurrence) was captured in the study/as an efficacy measure. Therefore it was not reported as an SAE. Progression/recurrence of the tumor was recorded in the clinical assessments in the electronic case report form (eCRF). Death due to progressive disease was recorded on a specific form in the eCRF but not as an SAE.
| Subjects | Cohort A-GSK2302024A Group | Cohort A-Placebo Group | Cohort B-GSK2302024A Group | Cohort B-Placebo Group | Cohort C-GSK2302024A Group | Cohort C-Placebo Group | Cohort D-GSK2302024A-D14 Group |
|---|---|---|---|---|---|---|---|
| Number of Subjects With Serious Adverse Events SAE(s) | 3 | 0 | 4 | 2 | 5 | 1 | 5 |
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
| Subjects | Cohort A-GSK2302024A Group | Cohort A-Placebo Group | Cohort B-GSK2302024A Group | Cohort B-Placebo Group | Cohort C-GSK2302024A Group | Cohort C-Placebo Group | Cohort D-GSK2302024A-D14 Group |
|---|---|---|---|---|---|---|---|
| Grade 0 | 12 | 5 | 8 | 4 | 6 | 2 | 1 |
| Grade 1 | 2 | 1 | 1 | 2 | 5 | 2 | 2 |
| Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade Unknown | 1 | 1 | 0 | 0 | 0 | 0 | 5 |
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
| Subjects | Cohort A-GSK2302024A Group | Cohort A-Placebo Group | Cohort B-GSK2302024A Group | Cohort B-Placebo Group | Cohort C-GSK2302024A Group | Cohort C-Placebo Group | Cohort D-GSK2302024A-D14 Group |
|---|---|---|---|---|---|---|---|
| Grade 0 | 10 | 5 | 8 | 6 | 7 | 3 | 1 |
| Grade 1 | 5 | 1 | 1 | 0 | 4 | 1 | 2 |
| Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade Unknown | 0 | 1 | 0 | 0 | 0 | 0 | 5 |
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
| Subjects | Cohort A-GSK2302024A Group | Cohort A-Placebo Group | Cohort B-GSK2302024A Group | Cohort B-Placebo Group | Cohort C-GSK2302024A Group | Cohort C-Placebo Group | Cohort D-GSK2302024A-D14 Group |
|---|---|---|---|---|---|---|---|
| Grade 0 | 12 | 7 | 1 | 0 | 0 | 0 | 2 |
| Grade 1 | 2 | 0 | 7 | 4 | 7 | 3 | 2 |
| Grade 2 | 1 | 0 | 0 | 0 | 4 | 1 | 0 |
| Grade 3 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade Unknown | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
| Subjects | Cohort A-GSK2302024A Group | Cohort A-Placebo Group | Cohort B-GSK2302024A Group | Cohort B-Placebo Group | Cohort C-GSK2302024A Group | Cohort C-Placebo Group | Cohort D-GSK2302024A-D14 Group |
|---|---|---|---|---|---|---|---|
| Grade 0 | 12 | 4 | 8 | 6 | 7 | 1 | 2 |
| Grade 1 | 3 | 2 | 1 | 0 | 4 | 3 | 1 |
| Grade 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade Unknown | 0 | 1 | 0 | 0 | 0 | 0 | 5 |
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
| Subjects | Cohort A-GSK2302024A Group | Cohort A-Placebo Group | Cohort B-GSK2302024A Group | Cohort B-Placebo Group | Cohort C-GSK2302024A Group | Cohort C-Placebo Group | Cohort D-GSK2302024A-D14 Group |
|---|---|---|---|---|---|---|---|
| Grade 0 | 15 | 5 | 9 | 6 | 11 | 2 | 3 |
| Grade 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Grade 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade Unknown | 0 | 1 | 0 | 0 | 0 | 0 | 5 |
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
| Subjects | Cohort A-GSK2302024A Group | Cohort A-Placebo Group | Cohort B-GSK2302024A Group | Cohort B-Placebo Group | Cohort C-GSK2302024A Group | Cohort C-Placebo Group | Cohort D-GSK2302024A-D14 Group |
|---|---|---|---|---|---|---|---|
| Grade 0 | 11 | 4 | 8 | 5 | 10 | 3 | 3 |
| Grade 1 | 4 | 2 | 1 | 1 | 1 | 1 | 0 |
| Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade Unknown | 4 | 1 | 0 | 0 | 0 | 0 | 5 |
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
| Subjects | Cohort A-GSK2302024A Group | Cohort A-Placebo Group | Cohort B-GSK2302024A Group | Cohort B-Placebo Group | Cohort C-GSK2302024A Group | Cohort C-Placebo Group | Cohort D-GSK2302024A-D14 Group |
|---|---|---|---|---|---|---|---|
| Grade 0 | 15 | 6 | 9 | 6 | 11 | 4 | 4 |
| Grade 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade Unknown | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
| Subjects | Cohort A-GSK2302024A Group | Cohort A-Placebo Group | Cohort B-GSK2302024A Group | Cohort B-Placebo Group | Cohort C-GSK2302024A Group | Cohort C-Placebo Group | Cohort D-GSK2302024A-D14 Group |
|---|---|---|---|---|---|---|---|
| Grade 0 | 14 | 3 | 8 | 6 | 11 | 4 | 3 |
| Grade 1 | 1 | 3 | 1 | 0 | 0 | 0 | 0 |
| Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade Unknown | 3 | 1 | 0 | 0 | 0 | 0 | 5 |
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
| Subjects | Cohort A-GSK2302024A Group | Cohort A-Placebo Group | Cohort B-GSK2302024A Group | Cohort B-Placebo Group | Cohort C-GSK2302024A Group | Cohort C-Placebo Group | Cohort D-GSK2302024A-D14 Group |
|---|---|---|---|---|---|---|---|
| Grade 0 | 15 | 5 | 7 | 6 | 10 | 4 | 3 |
| Grade 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 |
| Grade 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade Unknown | 0 | 1 | 0 | 0 | 0 | 0 | 5 |
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
| Subjects | Cohort A-GSK2302024A Group | Cohort A-Placebo Group | Cohort B-GSK2302024A Group | Cohort B-Placebo Group | Cohort C-GSK2302024A Group | Cohort C-Placebo Group | Cohort D-GSK2302024A-D14 Group |
|---|---|---|---|---|---|---|---|
| Grade 0 | 14 | 4 | 9 | 6 | 10 | 4 | 3 |
| Grade 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 |
| Grade 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade Unknown | 0 | 1 | 0 | 0 | 0 | 0 | 5 |
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
| Subjects | Cohort A-GSK2302024A Group | Cohort A-Placebo Group | Cohort B-GSK2302024A Group | Cohort B-Placebo Group | Cohort C-GSK2302024A Group | Cohort C-Placebo Group | Cohort D-GSK2302024A-D14 Group |
|---|---|---|---|---|---|---|---|
| Grade 0 | 13 | 6 | 9 | 5 | 9 | 3 | 3 |
| Grade 1 | 1 | 0 | 0 | 1 | 2 | 1 | 0 |
| Grade 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade Unknown | 0 | 1 | 0 | 0 | 0 | 0 | 5 |
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
| Subjects | Cohort A-GSK2302024A Group | Cohort A-Placebo Group | Cohort B-GSK2302024A Group | Cohort B-Placebo Group | Cohort C-GSK2302024A Group | Cohort C-Placebo Group | Cohort D-GSK2302024A-D14 Group |
|---|---|---|---|---|---|---|---|
| Grade 0 | 12 | 6 | 5 | 4 | 10 | 3 | 3 |
| Grade 1 | 3 | 0 | 3 | 1 | 1 | 1 | 0 |
| Grade 2 | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade Unknown | 0 | 1 | 0 | 0 | 0 | 0 | 5 |
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
| Subjects | Cohort A-GSK2302024A Group | Cohort A-Placebo Group | Cohort B-GSK2302024A Group | Cohort B-Placebo Group | Cohort C-GSK2302024A Group | Cohort C-Placebo Group | Cohort D-GSK2302024A-D14 Group |
|---|---|---|---|---|---|---|---|
| Grade 0 | 15 | 6 | 9 | 6 | 10 | 4 | 3 |
| Grade 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Grade 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade Unknown | 0 | 1 | 0 | 0 | 0 | 0 | 5 |
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
| Subjects | Cohort A-GSK2302024A Group | Cohort A-Placebo Group | Cohort B-GSK2302024A Group | Cohort B-Placebo Group | Cohort C-GSK2302024A Group | Cohort C-Placebo Group | Cohort D-GSK2302024A-D14 Group |
|---|---|---|---|---|---|---|---|
| Grade 0 | 15 | 6 | 5 | 6 | 11 | 4 | 3 |
| Grade 1 | 0 | 0 | 4 | 0 | 0 | 0 | 0 |
| Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade Unknown | 0 | 1 | 0 | 0 | 0 | 0 | 5 |
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
| Subjects | Cohort A-GSK2302024A Group | Cohort A-Placebo Group | Cohort B-GSK2302024A Group | Cohort B-Placebo Group | Cohort C-GSK2302024A Group | Cohort C-Placebo Group | Cohort D-GSK2302024A-D14 Group |
|---|---|---|---|---|---|---|---|
| Grade 0 | 9 | 4 | 0 | 0 | 2 | 1 | 1 |
| Grade 1 | 5 | 2 | 3 | 2 | 3 | 1 | 1 |
| Grade 2 | 1 | 1 | 5 | 2 | 5 | 1 | 2 |
| Grade 3 | 0 | 0 | 1 | 2 | 1 | 1 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade Unknown | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
| Subjects | Cohort A-GSK2302024A Group | Cohort A-Placebo Group | Cohort B-GSK2302024A Group | Cohort B-Placebo Group | Cohort C-GSK2302024A Group | Cohort C-Placebo Group | Cohort D-GSK2302024A-D14 Group |
|---|---|---|---|---|---|---|---|
| Grade 0 | 15 | 7 | 9 | 6 | 11 | 4 | 4 |
| Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade Unknown | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
| Subjects | Cohort A-GSK2302024A Group | Cohort A-Placebo Group | Cohort B-GSK2302024A Group | Cohort B-Placebo Group | Cohort C-GSK2302024A Group | Cohort C-Placebo Group | Cohort D-GSK2302024A-D14 Group |
|---|---|---|---|---|---|---|---|
| Grade 0 | 12 | 6 | 7 | 5 | 10 | 3 | 0 |
| Grade 1 | 3 | 0 | 1 | 1 | 1 | 0 | 0 |
| Grade 2 | 0 | 1 | 1 | 0 | 0 | 0 | 1 |
| Grade 3 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Grade Unknown | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
| Subjects | Cohort A-GSK2302024A Group | Cohort A-Placebo Group | Cohort B-GSK2302024A Group | Cohort B-Placebo Group | Cohort C-GSK2302024A Group | Cohort C-Placebo Group | Cohort D-GSK2302024A-D14 Group |
|---|---|---|---|---|---|---|---|
| Grade 0 | 14 | 6 | 8 | 5 | 5 | 2 | 2 |
| Grade 1 | 1 | 1 | 1 | 1 | 5 | 2 | 2 |
| Grade 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade Unknown | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
| Subjects | Cohort A-GSK2302024A Group | Cohort A-Placebo Group | Cohort B-GSK2302024A Group | Cohort B-Placebo Group | Cohort C-GSK2302024A Group | Cohort C-Placebo Group | Cohort D-GSK2302024A-D14 Group |
|---|---|---|---|---|---|---|---|
| Grade 0 | 13 | 7 | 6 | 3 | 7 | 2 | 0 |
| Grade 1 | 2 | 0 | 2 | 2 | 4 | 1 | 1 |
| Grade 2 | 0 | 0 | 1 | 1 | 0 | 1 | 0 |
| Grade 3 | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade Unknown | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
| Subjects | Cohort A-GSK2302024A Group | Cohort A-Placebo Group | Cohort B-GSK2302024A Group | Cohort B-Placebo Group | Cohort C-GSK2302024A Group | Cohort C-Placebo Group | Cohort D-GSK2302024A-D14 Group |
|---|---|---|---|---|---|---|---|
| Any AE(s) Grade 1 | 6 | 1 | 0 | 0 | 0 | 0 | 0 |
| Any AE(s) Grade 2 | 6 | 4 | 6 | 0 | 4 | 3 | 2 |
| Any AE(s) Grade 3 | 3 | 0 | 0 | 5 | 3 | 0 | 1 |
| Any AE(s) Grade 4 | 0 | 0 | 2 | 1 | 4 | 1 | 4 |
| Any AE(s) Grade 5 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Any AE(s) | 15 | 5 | 9 | 6 | 11 | 4 | 7 |
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
| Subjects | Cohort A-GSK2302024A Group | Cohort A-Placebo Group | Cohort B-GSK2302024A Group | Cohort B-Placebo Group | Cohort C-GSK2302024A Group | Cohort C-Placebo Group | Cohort D-GSK2302024A-D14 Group |
|---|---|---|---|---|---|---|---|
| Any related AE(s) Grade 1 | 7 | 2 | 0 | 0 | 5 | 0 | 2 |
| Any related AE(s) Grade 2 | 4 | 0 | 3 | 0 | 1 | 1 | 4 |
| Any related AE(s) Grade 3 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Any related AE(s) Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Any related AE(s) Grade 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Any related AE(s) | 12 | 2 | 3 | 0 | 7 | 1 | 6 |
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
| Subjects | Cohort A-GSK2302024A Group | Cohort A-Placebo Group | Cohort B-GSK2302024A Group | Cohort B-Placebo Group | Cohort C-GSK2302024A Group | Cohort C-Placebo Group | Cohort D-GSK2302024A-D14 Group |
|---|---|---|---|---|---|---|---|
| Any SAE(s) Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Any SAE(s) Grade 2 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Any SAE(s) Grade 3 | 2 | 0 | 0 | 1 | 1 | 0 | 1 |
| Any SAE(s) Grade 4 | 0 | 0 | 2 | 1 | 4 | 1 | 4 |
| Any SAE(s) Grade 5 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Any SAE(s) | 3 | 0 | 4 | 2 | 5 | 1 | 5 |
Criteria for Adverse Events (CTCAE), version 4.0 of May 28, 2009. Grades refer to the severity of the AE: mild (grade 1), moderate (grade 2), severe or medically significant (grade 3), life-threatening (grade 4) and death (grade 5).
| Subjects | Cohort A-GSK2302024A Group | Cohort A-Placebo Group | Cohort B-GSK2302024A Group | Cohort B-Placebo Group | Cohort C-GSK2302024A Group | Cohort C-Placebo Group | Cohort D-GSK2302024A-D14 Group |
|---|---|---|---|---|---|---|---|
| Any related SAE(s) Grade 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Any related SAE(s) Grade 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Any related SAE(s) Grade 3 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Any related SAE(s) Grade 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Any related SAE(s) Grade 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Any related SAE(s) | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
The pathological response in lymph nodes was evaluated by presence or absence of tumor cells by histopathological examination. Partial responses mark the disappearance of tumor cells, with only small clusters or dispersed cells remaining (more than 90% loss) while complete response indicate no identifiable malignant cells. However, ductal carcinoma in situ may be present.
| Subjects | Cohort A-GSK2302024A Group | Cohort A-Placebo Group | Cohort B-GSK2302024A Group | Cohort B-Placebo Group | Cohort C-GSK2302024A Group | Cohort C-Placebo Group | Cohort D-GSK2302024A-D14 Group |
|---|---|---|---|---|---|---|---|
| Partial respose | 4 | 3 | 5 | 3 | 3 | 1 | 3 |
| Complete response | 0 | 0 | 0 | 2 | 6 | 3 | 1 |
Collected over AEs were reported during the treatment period and up to 30 days post last administration. SAEs during the entire study period (Week 0 to Week 26/32).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A-GSK2302024A Group | 0/15 (0%) | 3/15 (20%) | 15/15 (100%) |
| Cohort A-Placebo Group | 0/7 (0%) | 0/7 (0%) | 5/7 (71.4%) |
| Cohort B-GSK2302024A Group | 1/9 (11.1%) | 4/9 (44.4%) | 9/9 (100%) |
| Cohort B-Placebo Group | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| Cohort C-GSK2302024A Group | 0/11 (0%) | 5/11 (45.5%) | 11/11 (100%) |
| Cohort C-Placebo Group | 0/4 (0%) | 1/4 (25%) | 4/4 (100%) |
| Cohort D-GSK2302024A-D14 Group | 0/8 (0%) | 5/8 (62.5%) | 7/8 (87.5%) |
| Event | Cohort A-GSK2302024A Group | Cohort A-Placebo Group | Cohort B-GSK2302024A Group | Cohort B-Placebo Group | Cohort C-GSK2302024A Group | Cohort C-Placebo Group | Cohort D-GSK2302024A-D14 Group |
|---|---|---|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 0/15 | 0/7 | 1/9 | 1/6 | 4/11 | 0/4 | 3/8 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/15 | 0/7 | 1/9 | 1/6 | 1/11 | 1/4 | 2/8 |
| DiarrhoeaGastrointestinal disorders | 0/15 | 0/7 | 0/9 | 0/6 | 2/11 | 0/4 | 0/8 |
| LeukopeniaBlood and lymphatic system disorders | 0/15 | 0/7 | 1/9 | 0/6 | 1/11 | 0/4 | 1/8 |
| StomatitisGastrointestinal disorders | 0/15 | 0/7 | 0/9 | 0/6 | 0/11 | 0/4 | 1/8 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/15 | 0/7 | 0/9 | 0/6 | 0/11 | 0/4 | 1/8 |
| DeathGeneral disorders | 0/15 | 0/7 | 1/9 | 0/6 | 0/11 | 0/4 | 0/8 |
| CholecystitisHepatobiliary disorders | 0/15 | 0/7 | 1/9 | 0/6 | 0/11 | 0/4 | 0/8 |
| HyponatraemiaMetabolism and nutrition disorders | 0/15 | 0/7 | 1/9 | 0/6 | 0/11 | 0/4 | 0/8 |
| NauseaGastrointestinal disorders | 0/15 | 0/7 | 0/9 | 0/6 | 1/11 | 0/4 | 0/8 |
| Event | Cohort A-GSK2302024A Group | Cohort A-Placebo Group | Cohort B-GSK2302024A Group | Cohort B-Placebo Group | Cohort C-GSK2302024A Group | Cohort C-Placebo Group | Cohort D-GSK2302024A-D14 Group |
|---|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 3/15 | 1/7 | 8/9 | 4/6 | 7/11 | 4/4 | 2/8 |
| AlopeciaSkin and subcutaneous tissue disorders | 0/15 | 0/7 | 9/9 | 5/6 | 8/11 | 3/4 | 3/8 |
| NauseaGastrointestinal disorders | 2/15 | 0/7 | 6/9 | 0/6 | 8/11 | 2/4 | 3/8 |
| Injection site painGeneral disorders | 4/15 | 0/7 | 0/9 | 0/6 | 4/11 | 0/4 | 4/8 |
| Mucosal inflammationGeneral disorders | 0/15 | 0/7 | 3/9 | 0/6 | 3/11 | 2/4 | 0/8 |
| LeukopeniaBlood and lymphatic system disorders | 0/15 | 0/7 | 0/9 | 3/6 | 0/11 | 0/4 | 2/8 |
| Peripheral sensory neuropathyNervous system disorders | 0/15 | 1/7 | 2/9 | 0/6 | 5/11 | 2/4 | 0/8 |
| DysgeusiaNervous system disorders | 0/15 | 0/7 | 2/9 | 3/6 | 0/11 | 0/4 | 2/8 |
| PruritusSkin and subcutaneous tissue disorders | 0/15 | 0/7 | 0/9 | 0/6 | 0/11 | 2/4 | 0/8 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/15 | 2/7 | 2/9 | 0/6 | 3/11 | 2/4 | 0/8 |
| Age, Continuous(Years) | Cohort A-GSK2302024A Group | Cohort A-Placebo Group | Cohort B-GSK2302024A Group | Cohort B-Placebo Group | Cohort C-GSK2302024A Group | Cohort C-Placebo Group | Cohort D-GSK2302024A-D14 Group | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 69.3 ± 10.4 | 70.9 ± 7.1 | 49.3 ± 15.6 | 60.7 ± 9.8 | 52.9 ± 10.6 | 53.3 ± 6.2 | 49.6 ± 8.7 | 58.9 ± 10.2 |
| Sex: Female, Male(Participants) | Cohort A-GSK2302024A Group | Cohort A-Placebo Group | Cohort B-GSK2302024A Group | Cohort B-Placebo Group | Cohort C-GSK2302024A Group | Cohort C-Placebo Group | Cohort D-GSK2302024A-D14 Group | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 15 | 7 | 9 | 6 | 11 | 4 | 8 | 60 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Plan to share: Yes — IPD for this study is available via the Clinical Study Data Request site (click on the link provided below).
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Apr 2011 to primary completion in Nov 2014, 43 months.
Results were first posted in May 2017, 2 years 6 months after primary completion. A results delay was requested in Mar 2015.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Aromatase inhibitors · Fluorouracil · Cyclophosphamide · Docetaxel · Doxorubicin · Epirubicin · Paclitaxel